Pharmafile Logo
Pharmafocus logo
Advanced Search

relapsing-remitting multiple sclerosis

Showing 2 posts of 2 posts found.

a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

Sanofi reveals promising data for relapsing remitting MS treatment

September 20, 2016
Manufacturing and Production, Research and Development RRMS, Sanofi, relapsing remitting multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi Genzyme, the speciality care global business unit of the French pharma firm announced six-year investigational data on Lemtrada (alemtuzumab) …

News
Genzyme

Genzyme’s Lemtrada shows five-year efficacy in extended trials

October 8, 2015
Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis

Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025